• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Sunday, May 29, 2022
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Exosome formulation developed to deliver antibodies for choroidal neovascularization therapy

Bioengineer by Bioengineer
July 26, 2021
in Health
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: TIAN Ying and ZHANG Fan

Researchers from the Institute of Process Engineering (IPE) of the Chinese Academy of Sciences, Beijing Chaoyang Hospital and the University of Queensland have developed a new formulation based on regulatory T-cell exosomes (rEXS) to deliver vascular endothelial growth factor (VEGF) antibodies for choroidal neovascularization therapy.

The study was published in Nature Biomedical Engineering on July 26.

Ocular neovascularization is often associated with age-related macular degeneration, diabetic retinopathy and other ocular diseases, which can cause severe vision loss.

The present treatment for ocular neovascular disease in clinic is intravitreal injection of VEGF antibodies (aV) to block the activity of VEGF and suppress pathogenic angiogenesis. However, this therapy alone faces problems of fast metabolism with the aqueous humor, poor accumulation in lesions and limited efficacy. A considerable proportion of patients still show incomplete response to above aV treatment.

In this study, the researchers collected aqueous humor samples from a large cohort of patients and quantified VEGF and other proinflammatory cytokines. “We observed a strong association between inflammation and high VEGF expression in aqueous humor samples,” said Prof. TAO Yong from Beijing Chaoyang Hospital. Thus, they proposed a synergistic therapeutic approach that combines anti-VEGF and anti-inflammatory therapies.

Following this approach, exosomes isolated from regulatory T-cells were utilized to conjugate aV using a peptide linker (cL), which was subject to cleavage by matrix metalloproteinases (MMPs) in inflammatory lesions. “This design concept could achieve efficient spatiotemporal delivery for combination therapy. After intravitreal injection, rEXS-cL-aV exploited the ability of rEXS to localize in neovascularization lesions and, upon MMP-mediated cleavage, released rEXS and aV to suppress inflammation and VEGF activity, respectively,” said Prof. WEI Wei from IPE.

The potent therapeutic efficacies were confirmed in both murine and nonhuman primate models of choroidal neovascularization. “This study is still at the preclinical stage. Given that rEXS can be produced from the patients’ own cells and aV has been approved for clinical use, our rEXS-cL-aV has the potential for translation to clinic,” said Prof. YU Di from the University of Queensland.

A peer reviewer from Nature Biomedical Engineering said, “The technology is novel and the treatment efficacy is impressive.” The reviewer also emphasized that “collectively, the work provides a substantial technological and potentially therapeutic advance for the treatment of neovascular disease.”

###

Media Contact
LI Xiangyu
[email protected]

Original Source

https://english.cas.cn/

Related Journal Article

http://dx.doi.org/10.1038/s41551-021-00764-3

Tags: Biomedical/Environmental/Chemical EngineeringMedicine/HealthOphthalmology
Share15Tweet9Share3ShareShareShare2

Related Posts

Oleogel formulations are developed for pediatric drug administration

Biomedical engineers design drug-delivery solution for low-resource settings

May 27, 2022
Goldkorn-Amir

Cell-free DNA methylation used to predict chemo benefit in bladder cancer

May 26, 2022

Asymptomatic SARS-CoV-2 infections responsible for spreading of COVID-19 less than symptomatic infections

May 26, 2022

Harsher COVID-19 restrictions associated with faster “pandemic fatigue”

May 26, 2022
Please login to join discussion

POPULAR NEWS

  • Masks

    Hidden benefit: Facemasks may reduce severity of COVID-19 and pressure on health systems, researchers find

    44 shares
    Share 18 Tweet 11
  • Breakthrough in estimating fossil fuel CO2 emissions

    46 shares
    Share 18 Tweet 12
  • Sweet discovery could drive down inflammation, cancers and viruses

    43 shares
    Share 17 Tweet 11
  • Wearable mask allows vegetative patients to communicate by breathing

    38 shares
    Share 15 Tweet 10

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

Weather/StormsVehiclesUrbanizationZoology/Veterinary ScienceVaccineWeaponryViolence/CriminalsVirologyVaccinesUrogenital SystemUniversity of WashingtonVirus

Recent Posts

  • Virtual biopsy set to transform heart transplant care
  • Fastest carbon dioxide catcher heralds new age for direct air capture
  • Joint research revealed the importance of anthropogenic vapors on haze pollution over Hong Kong and Mainland China’s megacities
  • Seeing how odor is processed in the brain
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Posting....